Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: An Italian prostatic cancer project (P.O.N.CA.P.) study.

F. Boccardo, A. Decensi, D. Guarneri, A. Rubagotti, T. Massa, G. Martorana, C. Giberti, G. B. Cerruti, F. Tani, A. Zanollo, T. Germinale, C. Borzone, F. Perri, E. Usai, L. Santi, L. Giuliani

Research output: Contribution to journalArticle

Abstract

Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D-TRP-6 LH-RH ('Decapeptyl') for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn-RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down-regulation of testicular LH receptors. Of 88 patients evaluable for response about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.

Original languageEnglish
Pages (from-to)243-255
Number of pages13
JournalProstate
Volume11
Issue number3
Publication statusPublished - 1987

Fingerprint

Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Triptorelin Pamoate
LH Receptors
Castration
Testosterone
Reference Values
Down-Regulation
Carcinoma
Bone and Bones
Pain
Therapeutics
Serum
Psychologic Desensitization

ASJC Scopus subject areas

  • Urology

Cite this

Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer : An Italian prostatic cancer project (P.O.N.CA.P.) study. / Boccardo, F.; Decensi, A.; Guarneri, D.; Rubagotti, A.; Massa, T.; Martorana, G.; Giberti, C.; Cerruti, G. B.; Tani, F.; Zanollo, A.; Germinale, T.; Borzone, C.; Perri, F.; Usai, E.; Santi, L.; Giuliani, L.

In: Prostate, Vol. 11, No. 3, 1987, p. 243-255.

Research output: Contribution to journalArticle

Boccardo, F, Decensi, A, Guarneri, D, Rubagotti, A, Massa, T, Martorana, G, Giberti, C, Cerruti, GB, Tani, F, Zanollo, A, Germinale, T, Borzone, C, Perri, F, Usai, E, Santi, L & Giuliani, L 1987, 'Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: An Italian prostatic cancer project (P.O.N.CA.P.) study.', Prostate, vol. 11, no. 3, pp. 243-255.
Boccardo, F. ; Decensi, A. ; Guarneri, D. ; Rubagotti, A. ; Massa, T. ; Martorana, G. ; Giberti, C. ; Cerruti, G. B. ; Tani, F. ; Zanollo, A. ; Germinale, T. ; Borzone, C. ; Perri, F. ; Usai, E. ; Santi, L. ; Giuliani, L. / Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer : An Italian prostatic cancer project (P.O.N.CA.P.) study. In: Prostate. 1987 ; Vol. 11, No. 3. pp. 243-255.
@article{9696687aed214e72988a83e191efd62d,
title = "Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: An Italian prostatic cancer project (P.O.N.CA.P.) study.",
abstract = "Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D-TRP-6 LH-RH ('Decapeptyl') for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn-RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down-regulation of testicular LH receptors. Of 88 patients evaluable for response about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.",
author = "F. Boccardo and A. Decensi and D. Guarneri and A. Rubagotti and T. Massa and G. Martorana and C. Giberti and Cerruti, {G. B.} and F. Tani and A. Zanollo and T. Germinale and C. Borzone and F. Perri and E. Usai and L. Santi and L. Giuliani",
year = "1987",
language = "English",
volume = "11",
pages = "243--255",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer

T2 - An Italian prostatic cancer project (P.O.N.CA.P.) study.

AU - Boccardo, F.

AU - Decensi, A.

AU - Guarneri, D.

AU - Rubagotti, A.

AU - Massa, T.

AU - Martorana, G.

AU - Giberti, C.

AU - Cerruti, G. B.

AU - Tani, F.

AU - Zanollo, A.

AU - Germinale, T.

AU - Borzone, C.

AU - Perri, F.

AU - Usai, E.

AU - Santi, L.

AU - Giuliani, L.

PY - 1987

Y1 - 1987

N2 - Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D-TRP-6 LH-RH ('Decapeptyl') for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn-RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down-regulation of testicular LH receptors. Of 88 patients evaluable for response about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.

AB - Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the depot formulation of D-TRP-6 LH-RH ('Decapeptyl') for up to 33 months. Serum testosterone (T) levels were significantly reduced to castration levels within 4 weeks and maintained persistently low. Similarly, LH levels were decreased, although they remained in the normal range. Stimulation tests with either Gn-RH or HCG in course of treatment showed the achievement of a complete pituitary desensitization and almost a complete down-regulation of testicular LH receptors. Of 88 patients evaluable for response about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained without major side effects. These results indicate that the depot formulation of D-TRP-6 LH-RH offers an effective therapeutic alternative for patients with advanced prostatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023499491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023499491&partnerID=8YFLogxK

M3 - Article

C2 - 2960957

AN - SCOPUS:0023499491

VL - 11

SP - 243

EP - 255

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 3

ER -